/
Oncology
Ewing Sarcoma
28
Pipeline Programs↗
22
Active Trials↗
19
Companies Involved↗
Ewing sarcoma is an emerging landscape with 28 programs across 19 companies. The most active players are Beijing Konruns Pharmaceutical Co., Ltd., Amgen. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 15
Phase 29
Phase 312
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
20 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 93% of 28 pipeline programs.
Analysis
Trial Status
58
clinical trials
Completed21 · 36%
Recruiting14 · 24%
Terminated8 · 14%
Active, not recruiting6 · 10%
Withdrawn3 · 5%
Unknown status3 · 5%
Other3 · 5%
Clinical Trials
Trial Activity
58 trials
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma
Recruiting·—·Phase 2·NCT05968768·24 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)